A Phase 1 interventional study of BMS-986256 and Placebo in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-16.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effects of the experimental medication BMS-986256 in healthy participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ascending single doses of BMS-986256
Drug: BMS-986256 · Other: Placebo
Ascending multiple doses of BMS-986256
Drug: BMS-986256 · Other: Placebo
Sequential multiple doses of BMS-986256
Drug: BMS-986256 · Other: Placebo
Specified dose on specified days
Specified dose on specified days
Number of Serious Adverse Events (SAE)
Time frame: Up to 46 days
Number of deaths
Time frame: Up to 46 days
Number of clinically significant changes in ECG, vital signs, physical examination findings, or clinical laboratory assessments
Time frame: Up to 44 days
Number of Adverse Events (AEs) leading to early discontinuation
Time frame: Up to 44 days
Maximum concentration (Cmax)
Time frame: Up to 44 days
Time of maximum concentration (Tmax)
Time frame: Up to 44 days
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-T)]
Time frame: Up to 44 days
Area under the plasma concentration-time curve extrapolated to infinity [AUC(INF)]
Time frame: Up to 44 days
Terminal elimination rate constant (kel)
Time frame: Up to 44 days
Terminal elimination half-life (T-half)
Time frame: Up to 44 days
Apparent oral clearance (CL/F)
Time frame: Up to 44 days
Metabolite ratio for AUC(INF) [MR(AUC[INF])]
Time frame: Up to 44 days
Metabolite ratio of Cmax [MR(Cmax)]
Time frame: Up to 44 days
Apparent volume of distribution at terminal phase (Vz/F)
Time frame: Up to 44 days
Plasma concentration immediately prior to dosing (Ctrough)
Time frame: Up to 44 days
Area under the plasma concentration-time curve over the dosing interval [AUC(TAU)]
Time frame: Up to 44 days
Accumulation ratio of Ctrough [AR(Ctrough)]
Time frame: Up to 44 days
Accumulation ratio of AUC(TAU) [AR(AUC[TAU])]
Time frame: Up to 44 days
Accumulation ratio of Cmax [AR(Cmax)]
Time frame: Up to 44 days
Metabolite ratio for AUC(TAU) [MR(AUC[TAU])]
Time frame: Up to 44 days
Ran from Aug 2018 to primary completion in Oct 2019, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimetoran